Immunome (IMNM) Operating Expenses (2019 - 2026)
Immunome's (IMNM) quarterly Operating Expenses came in at $59.3 million in Q1 2026, up 24.74% YoY from $47.6 million in Q1 2025, and down 18.57% on a QoQ basis from $72.9 million in Q4 2025.
Immunome (IMNM) Operating Expenses (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Operating Expenses data on file, last reported at $59.3 million in Q1 2026.
- Quarterly Operating Expenses rose 24.74% year-over-year to $59.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $242.8 million (up 6.0% YoY) and the FY2025 annual result came in at $231.1 million, down 26.61% from the prior year.
- Operating Expenses slipped to $59.3 million in Q1 2026, from $72.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $133.3 million in Q1 2024 to a low of $6.8 million in Q1 2023.
- A 5-year average of $45.0 million and a median of $47.6 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 1850.67% — and 2025, when it sank 64.33%.
- Tracing IMNM's Operating Expenses over 5 years: stood at $7.8 million in 2022, then jumped by 1164.66% to $98.5 million in 2023, then retreated by 12.97% to $85.7 million in 2024, then dropped by 14.99% to $72.9 million in 2025, then decreased by 18.57% to $59.3 million in 2026.
- The last three Operating Expenses figures came in at $59.3 million (Q1 2026), $72.9 million (Q4 2025), and $60.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 78.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.14 Mn |
| Mar 31, 2026 | 59.33 Mn |
| Dec 31, 2025 | 72.86 Mn |
| Sep 30, 2025 | 60.14 Mn |
| Jun 30, 2025 | 50.49 Mn |
| Mar 31, 2025 | 47.56 Mn |
| Dec 31, 2024 | 85.71 Mn |
| Sep 30, 2024 | 53.43 Mn |
| Jun 30, 2024 | 42.37 Mn |
| Mar 31, 2024 | 133.33 Mn |
| Dec 31, 2023 | 98.48 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 10.04 Mn |
| Mar 31, 2023 | 6.84 Mn |
| Dec 31, 2022 | 7.79 Mn |
| Sep 30, 2022 | 8.53 Mn |
| Jun 30, 2022 | 8.93 Mn |
| Mar 31, 2022 | 11.65 Mn |
| Dec 31, 2021 | 7.84 Mn |
| Sep 30, 2021 | 7.72 Mn |